SEATTLE--(BUSINESS WIRE)--Light Sciences Oncology (LSO) (NASDAQ:LSON) today announced a major initiative to strengthen its intellectual property position and extend the range of its Light Infusion Therapy (Litx™). On December 29, 2006, LSO purchased the assets of its former parent company, Light Sciences, LLC (LSLLC) through the issuance of common stock. As a result of the purchase, LSO now owns all patents and substantially all of the other assets of LSLLC and its subsidiaries: Visient Therapeutics, Inc.; Vascular Reconditioning, Inc.; Light Devices, Inc.; Light Sciences Adipose, Inc.; and Light Sciences R&D, LLC.
